Human renal cell carcinoma xenograft: morphology, growth and chemosensitivities.
A primary human renal clear cell carcinoma has been developed as a xenograft (JDF-1). Passage 7 of the JDF-1 tumor retained the microscopic morphology of the primary tumor, electron micrographs have confirmed its epithelial characteristics and karyotyping of a subsequent passage has proved it is not a murine hybrid. Immunoperoxidase studies using a panel of murine monoclonal antibodies demonstrate an antigenic phenotype specific for human renal cancer. In vitro chemosensitivities of the JDF-1 tumor were determined by the double-layer soft-agar clonogenic assay method. JDF-1 showed no significant sensitivities to several standard chemotherapeutic agents, but alpha-2-interferon and difluoromethylornithine in combination synergistically inhibited its growth by 74 per cent.
D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000473:pathology*; D000518:Eflornithine; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008854:Microscopy, Electron; D009368:Neoplasm Transplantation; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology; D014183:Transplantation, Heterologous; D014410:Tumor Stem Cell Assay
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D007370:Interferon Type I; D009952:Ornithine; D000518:Eflornithine